Formulation and Evaluation of Chewable Tablets of Loratadine by Direct Compression Method
Jyoti Dahiya, Pawan Jalwal, Shilpi Arora, Balvinder Singh, Renu
Since last few years, there has been an enhanced demand for more patient compliance dosage forms. For this an attempt has been made in the present work to design and evaluate chewable tablets. Chewable tablets have the advantages of both conventional tablet and liquid dosage formulation, especially in geriatric and pediatric. Oral route of administration has received more attention in the pharmaceutical field. Chewable dosage forms have been demonstrated to improve therapeutic efficacy and better bioavailability. Loratadine is a peripherally selective piperidine histamine receptor blocker, which competitively antagonizes histamine at the H1 receptor site. Histamine is amine autocoids which causes many signs and symptoms of allergy. It stimulates the cells to release chemicals that produce effects associated with allergy and commonly acts on α-adrenergic receptor or 5-HT receptor. Loratadine acts as a selective antagonist of peripheral histamine H1-receptor that serves to eliminate effects mediated by histamine (an endogenous chemical mediator released during allergic reactions) or block one type of histamine receptor (H1 receptor). Loratadine is a second-generation H1 histamine antagonist drug used to treat allergies. Loratadine is used for the symptomatic relief of allergy such as hay fever (allergic rhinitis), urticaria and seasonal allergies including sneezing, itchy and runny nose, and tearing and redness of the eyes.
How to cite this article:
Jyoti Dahiya, Pawan Jalwal, Shilpi Arora, Balvinder Singh, Renu. Formulation and Evaluation of Chewable Tablets of Loratadine by Direct Compression Method. Pharma Innovation 2015;4(5):97-99.